Medical Devices

USF lands 42 graduate programs in the top 100, with its medical school earning a Tier 1 research rating, cementing its role as a national powerhouse.

A new certification for AI-guided cardiac ultrasound seeks to solve the training and trust gap, making crucial heart scans more accessible for frontline providers.

Following positive safety data, Phanes Therapeutics expands trials for spevatamig, a first-in-class antibody targeting two cancer pathways at once.

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?

A new minimally invasive stent for complex aortic arch disease receives FDA approval, offering hope to high-risk patients previously deemed untreatable.

FDA approves a pivotal trial for a novel heart valve, potentially revolutionizing treatment for millions with severe tricuspid regurgitation.

A NJ surgeon performed the nation's first robotic-assisted shoulder replacement in an outpatient setting, heralding a new era of surgical precision.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

Ontario and Quebec expand public coverage for a potent cholesterol drug, offering a critical lifeline to thousands at risk of a second cardiovascular event.

As employers face staggering GLP-1 expenses, a new program aims to deliver measurable outcomes by integrating clinical support directly into pharmacy benefits.

A new poll shows two-thirds of workers are more likely to use GLP-1s with employer coverage, highlighting the role of cost, support, and stigma.

Life Sciences Ontario's new board appointments signal a strategic shift, bringing in leaders from medtech, agri-tech, pharma, and nuclear isotopes.

Backed by a $41.3M ARPA-H award, SonoNeu is pioneering sonogenetics, a non-invasive therapy using ultrasound to control cells and treat nerve pain.

With new clinical trial data showing its AI is superior for complex AFib, Volta Medical heads to a major conference to change the standard of care.

A new AI software that analyzes MRI scans has received a first-of-its-kind FDA classification, promising to help doctors differentiate complex brain disorders.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

A new award-winning serum promises 'glass skin' and enhances injectable results, tapping into a multi-billion dollar market. Here's the science behind it.

Nano Dimension sells its AME product line to cut costs, while buyer Inspira Technologies makes a high-risk pivot from medical devices to quantum computing.